# **Regimen Reference Order – CUTA – PACLitaxel + CARBOplatin**

ARIA: CUTA - [PACLitaxel + CARBOplatin]

Planned Course:Every 21 days until disease progression or unacceptable toxicityIndication for Use:Melanoma, Unresectable or Metastatic

## CVAD: At Provider's Discretion

## Proceed with treatment if:

ANC equal to or greater than 1.5 x 10<sup>9</sup>/L AND Platelets equal to or greater than 100 x 10<sup>9</sup>/L Contact Physician if parameters not met

# SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
Not Applicable				

# **Treatment Regimen – CUTA – PACLitaxel + CARBOplatin**

Drug	Dose	CCMB Administration Guideline
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
aprepitant	125 mg	Orally 1 hour pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u><b>1 hour</b></u> prior to PACLitaxel *Nursing Alert: PACLitaxel starts <b>1 hour after completion</b> of dexamethasone infusion
Wait 1 hour after co	mpletion of IV pre-medic	ation(s) before starting PACLitaxel
PACLitaxel	175 mg/m <sup>2</sup>	IV in normal saline 500 mL over 3 hours, following the administration rates below:
		Administer at 100 mL/hour for 15 minutes, then
		Administer remaining volume over 2 hours and 45 minutes
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug
CARBOplatin	AUC 5 mg/mL.min;	IV in D5W 250 mL over 30 minutes
	maximum dose	
	750 mg	
	(see table below)	

#### In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## **REQUIRED MONITORING**

### All Cycles

- CBC, serum creatinine, electrolytes and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
aprepitant	80 mg	Orally once daily on Days 2 and 3	
dexamethasone	8 mg	Orally once daily on Days 2 and 3	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	


# **DISCHARGE INSTRUCTIONS**

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

# ADDITIONAL INFORMATION

- PACLitaxel may cause progressive, irreversible neuropathy
- CARBOplatin dose considerations:
  - o CCMB Cutaneous DSG uses actual body weight to calculate GFR
  - CCMB Cutaneous DSG uses a maximum CARBOplatin dose of 750 mg for this regimen
  - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber





### AUC = Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation above may not be appropriate for some patient populations (for example, acute renal failure).

